Name (Synonyms) | Correlation | |
---|---|---|
drug19 | 40ml blood sample Wiki | 0.58 |
drug157 | COVID-19 infection Wiki | 0.58 |
drug146 | CHLORPROMAZINE (CPZ) Wiki | 0.58 |
drug669 | Questionnaire by phone call Wiki | 0.58 |
drug148 | COVID 19 diagnostic test by PCR Wiki | 0.58 |
drug808 | Symptoms questionnare Wiki | 0.58 |
drug773 | Standard of Care (SOC) Wiki | 0.58 |
drug152 | COVID-19 Serology Wiki | 0.41 |
drug151 | COVID-19 RT-PCR Wiki | 0.33 |
Name (Synonyms) | Correlation | |
---|---|---|
D015535 | Arthritis, Psoriatic NIH | 0.82 |
D008180 | Lupus Erythematosus, Systemic NIH | 0.67 |
D001167 | Arteritis NIH | 0.58 |
D025241 | Spondylarthritis NIH | 0.58 |
D011111 | Polymyalgia Rheumatica NIH | 0.58 |
D013700 | Giant Cell Arteritis NIH | 0.58 |
D012859 | Sjogren's Syndrome NIH | 0.58 |
D003095 | Collagen Diseases NIH | 0.41 |
D001327 | Autoimmune Diseases NIH | 0.41 |
D012216 | Rheumatic Diseases NIH | 0.41 |
Name (Synonyms) | Correlation |
---|
There are 3 clinical trials
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusionDescription: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusionDescription: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusionA team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective. This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus. When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.
Description: the prevalence and abundance of CD4+ T lymphocytes specifically recognizing SARS-CoV-2 in COVID-19 patients with inflammatory arthritis, in pre- and post-infection samples; in patients without COVID-19 and in healthy volunteers with or without COVID-19. Correlation of these cells with COVID-19 severity.
Measure: Prevalence and abundance of CD4+ T lymphocytes Time: 2 years